Top View
- FDA Warns About the Risk of Hepatitis B Reactivating in Some Patients Treated with Direct-Acting Antivirals for Hepatitis C
- Antiviral Activity Exerted by Natural Products Against Human Viruses
- Estonian Statistics on Medicines 2013 1/44
- Summary of Product Characteristics 1. Name Of
- “Entecavir in Severe Acute Hepatitis B” Pervaiz Majeed Zunga* Department of Internal Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India
- Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
- Version 9.0 October 2017
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir
- Position Statement on the Use of Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Virus Infection in Africa
- Hepatitis B Coinfection
- 7 Management of Hepatitis B and HIV Coinfection Clinical Protocol for the WHO European Region (2011 Revision)
- Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver D
- Baraclude® Rx Only
- Tenofovir Vs Entecavir for Hepatocellular Carcinoma Prevention in Patients with Chronic Hepatitis B One of These Things Is Not Like the Other Jennifer A
- Drug Discovery of Nucleos(T)Ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80Th Birthday
- Free PDF Download
- Prevention and Treatment of Cancer-Related Infections Discussion
- Baraclude, INN-Entecavir
- Medication Guidelines for Solid Organ Transplants
- Approved Antiviral Drugs Over the Past 50 Years
- The Only Oral Antiviral for Chronic HBV Infection in Adults Without Required Renal Dosage Adjustment1-4
- VIREAD® (Tenofovir
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Clinical Trial of Entecavir/Peginterferon in Immune
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- Vemlidy® (Tenofovir Alafenamide) P&T Approval Date 6/2017, 10/2018, 10/2019, 10/2020 Effective Date 1/1/2021; Oxford Only: N/A
- Tenofovir Disoproxil Mylan, INN-Tenofovir Disoproxil Maleate
- Investigational Agent Promising for Hepatitis B
- SARS-Cov-2 Rdrp Inhibitors Selected from a Cell-Based SARS-Cov-2 Rdrp Activity Assay System
- Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials
- Guidelines for ATC Classification and DDD Assignment 2021
- Study Protocol
- Vemlidy, INN-Tenofovir Alafenamide
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- 2013 March (127): Treatment Guidelines
- Switching to Tenofovir Disoproxil Fumarate in Entecavir‑Treated Chronic Hepatitis B Patients: a Pilot Randomized Controlled Study
- Guidelines for ATC Classification and DDD Assignment 2013
- Summary of Risk Management Plan for BARACLUDE (Entecavir) This Is a Summary of the Risk Management Plan (RMP) for BARACLUDE
- Peginterferon Alfa-2A (Pegasys®) EOCCO POLICY
- Exploring the Selectivity of Guanine Scaffold in Anticancer Drug
- Outcomes of Sequential Therapy with Tenofovir Alafenamide After Long-Term Entecavir LIVER
- GENVOYA Safely and Effectively
- Tonic-Clonic Seizure in a Liver-Transplant Recipient Due to Concomitant Use of Colchicine with Cyclosporine a And
- WEB ANNEX J. TABLE of DRUG INTERACTIONS with ANTIRETROVIRAL DRUGS In: Updated Recommendations on First-Line and Second-Line Anti
- Screening for Hepatitis B Virus Infection in Nonpregnant
- Management of Patients with HIV and Hepatitis B Coinfection Carolina De La Flor, MD, James B
- BARACLUDE (Entecavir) Tablets • Decompensated Liver Disease (Adults): 1 Mg Once Daily
- SYSTEMATIC REVIEW: Drug-Drug Interactions Between Antiretrovirals
- Interferon Therapy – (1315)
- Summary of Key ARV Drug Interactions
- BARACLUDE (Greater Than Or Equal to 16 Years Old): 1 Mg Once Daily